Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Treatment with α1-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4ml from baseline in placebo patients but decreased by -0.25ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.

Original languageEnglish (US)
Pages (from-to)121-125
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume9
Issue number2
DOIs
StatePublished - Jun 2006

Fingerprint

Prostate
Placebos
Lower Urinary Tract Symptoms
Therapeutics
Apoptosis
Adrenergic Antagonists
Prostatic Hyperplasia
alfuzosin
Adrenergic Receptors

Keywords

  • α-blocker
  • Alfuzosin
  • Apoptosis
  • Benign prostatic hyperplasia
  • Prostate volume

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{d3bf42a162fc401fa6077f9290c068de,
title = "Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate",
abstract = "Treatment with α1-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4ml from baseline in placebo patients but decreased by -0.25ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.",
keywords = "α-blocker, Alfuzosin, Apoptosis, Benign prostatic hyperplasia, Prostate volume",
author = "Claus Roehrborn",
year = "2006",
month = "6",
doi = "10.1038/sj.pcan.4500849",
language = "English (US)",
volume = "9",
pages = "121--125",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate

AU - Roehrborn, Claus

PY - 2006/6

Y1 - 2006/6

N2 - Treatment with α1-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4ml from baseline in placebo patients but decreased by -0.25ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.

AB - Treatment with α1-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4ml from baseline in placebo patients but decreased by -0.25ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.

KW - α-blocker

KW - Alfuzosin

KW - Apoptosis

KW - Benign prostatic hyperplasia

KW - Prostate volume

UR - http://www.scopus.com/inward/record.url?scp=33745663261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745663261&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500849

DO - 10.1038/sj.pcan.4500849

M3 - Article

C2 - 16304557

AN - SCOPUS:33745663261

VL - 9

SP - 121

EP - 125

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -